These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12881387)

  • 1. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.
    Martin M; Spielmann M; Namer M; duBois A; Unger C; Dodwell D; Vodvarka P; Lind M; Calvert H; Casado A; Zelek L; Lluch A; Carrasco E; Kayitalire L; Zielinski C
    Ann Oncol; 2003 Aug; 14(8):1246-52. PubMed ID: 12881387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of Loubo® (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes.
    Deng QQ; Huang XE; Ye LH; Lu YY; Liang Y; Xiang J
    Asian Pac J Cancer Prev; 2013; 14(1):413-7. PubMed ID: 23534764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.
    Llombart-Cussac A; Theodoulou M; Rowland K; Clark RS; Nakamura T; Carrasco E; Cruciani G
    Clin Breast Cancer; 2006 Dec; 7(5):380-5. PubMed ID: 17239262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.
    Miles DW; Smith IE; Coleman RE; Calvert AH; Lind MJ
    Eur J Cancer; 2001 Jul; 37(11):1366-71. PubMed ID: 11435066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
    O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA
    Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.
    Spielmann M; Martin M; Namer M; duBois A; Unger C; Dodwell DJ
    Clin Breast Cancer; 2001 Apr; 2(1):47-51. PubMed ID: 11899382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer.
    Martin M; Blasinska-Morawiec M; Salas JF; Falcon S; Rolski J; Ferrari BL; Gulyas S; Liu Y; Benhadji KA
    Clin Breast Cancer; 2009 Aug; 9(3):155-60. PubMed ID: 19661038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.
    Amadori D; Carrasco E; Roesel S; Labianca R; Uziely B; Soldatenkova V; Moreau V; Desaiah D; Bauknecht T; Martin M
    Int J Oncol; 2013 May; 42(5):1778-85. PubMed ID: 23546172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Kouroussis Ch; Papakotoulas P; Kalbakis K; Tryfonidis K; Vardakis N; Poppis E; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 May; 69(5):1345-52. PubMed ID: 22349809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.
    Ma CX; Steen P; Rowland KM; Niedringhaus RD; Fitch TR; Kugler JW; Hillman DW; Perez EA; Ingle JN; Adjei AA
    Ann Oncol; 2006 Feb; 17(2):226-31. PubMed ID: 16303865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
    Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
    Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
    Pippen J; Elias AD; Neubauer M; Stokoe C; Vaughn LG; Wang Y; Orlando M; Shonukan O; Muscato J; O'Shaughnessy JA; Gralow J
    Clin Breast Cancer; 2010 Apr; 10(2):148-53. PubMed ID: 20299319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
    Dent SF; Gertler S; Verma S; Segal R; Young V; Goel R; Keller O; Canil C; Iscoe N
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):557-61. PubMed ID: 19593565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
    Miller DS; Blessing JA; Krasner CN; Mannel RS; Hanjani P; Pearl ML; Waggoner SE; Boardman CH
    J Clin Oncol; 2009 Jun; 27(16):2686-91. PubMed ID: 19332726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
    J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
    Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.